
Figure 2

## How many people will have their chronic back pain meaningfully improved (~30%) by different treatments?



Inadequate responder data for: acetaminophen, cannabinoids, muscle relaxants, anticonvulsants, tricyclic antidepressants, selective serotonin reuptake inhibitors, and topical NSAIDs.

\*Effect uncertain based on quality markers. To be reviewed by an upcoming guideline committee









## Figure 3

## Treatment Options for Chronic Low Back Pain

Benefits and Harms	Treatment	Withdrawals Due to Adverse Events*	Adverse Events (Examples)	Cost	Prescribing Comments
© Benefits likely exceed harms	Exercise	Not reported	Mild muscle soreness, joint pain, injuries	\$ to \$\$\$\$	Benefits consistent across trials.  May provide continued pain relief beyond study period. Type of exercise likely doesn't matter.
	Spinal Manipulation (Lumbar)	Not reported	Unknown	\$\$\$ to \$\$\$\$	Degree of benefit is uncertain.  Case reports have associated neck manipulation with stroke. <sup>2</sup>
Enefits may not exceed harms in some patients	Oral NSAIDs	Similar to placebo	Gastrointestinal, renal, and cardiovascular adverse effects	\$ to \$\$	Consider naproxen or ibuprofen. Diclofenac and COX-2 Inhibitors may increase cardiovascular disease risk.
	SNRIs (Duloxetine)	18% for SNRI versus 9% for placebo	Nausea, dizziness, somnolence	\$\$	Most trials studied duloxetine 60 – 120mg once daily. The number of people who benefit over placebo (about 10%) is similar to the number who stop for adverse events (about 9%).
⊗ No benefit	Corticosteroid Injections	Not reported	Infection, post-dural puncture headache	\$\$	Effects are not statistically different from placebo.
E) Harms likely exceed benefits	Opioids	27% for opioids versus 5% for placebo	Dependency, constipation, overdose, nausea, dizziness	\$\$ to \$\$\$	Lower risk of bias trials show no effect in chronic back pain but the risk of harm remains.
© Unclear benefits	Acupuncture	Similar to placebo	None consistently reported	\$\$\$ to \$\$\$\$	Efficacy of acupuncture disappears in trials >4 weeks and in higher quality studies.
	Rubefacients (Capsaicin)	Not reported	Heat or burning sensation, mild or moderate local erythema	\$ to \$\$	The absence of trials that last longer than 3 weeks makes it difficult to extrapolate for a chronic condition.

Cost approximates dollars per month: \$ = <25, \$\$ = 25-50, \$\$\$ = 50-100, \$\$\$\$ = >100

NSAIDs: Non-Steroidal Anti-Inflammatory Drugs, SNRI: Serotonin Norepinephrine Reuptake Inhibitors

Note: Insufficient responder data for acetaminophen, muscle relaxants, selective serotonin reuptake inhibitors, cannabinoids,  $tricyclic \ antidepressants, anticonvulsants, and \ topical\ NSAIDs\ to\ judge\ whether\ or\ not\ they\ are\ effective.$ 

\*Percents reported are statistically different from placebo







